Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
January 22, 2025 8:15 AM ESTRaymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)
The analyst comments "Quick take: 4Q results were solid with a 1% revenue beat and a 3% EPS beat. The revenue upside was driven by Innovative Medicine... More
